Zynerba fragile after pivotal failure
The implosion of Zygel’s fragile X study leaves its developer few places to turn.
Tisotumab’s cervical cancer efficacy falls off
But a 24% remission rate is still enough to get the project before the US regulator, analysts reckon.
Gilead finally prices its Covid-19 drug
By pricing remdesivir at $2,340 for a five-day course Gilead has kept investors on side, but others will be disappointed.
The dream is over for Intercept
The company blasts the US regulator as weeks of uncertainty for its lead drug in Nash end in a complete response letter.
No buyout for Uniqure
But a licensing deal with CSL could have underappreciated benefits, even if expectations were for something much bigger.
Myovant socks it to Orilissa
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.
Merck and Pfizer square up for pneumococcal vaccine fight
The rivals have taken different strategies with next-gen pneumococcal vaccines, which will be fighting for a blockbuster market that is Pfizer’s to lose.
Invitae ends medtech merger drought with ArcherDX deal
The cash-and-stock deal, worth $886m up front, is the first major liquid biopsy acquisition since Roche bought Foundation Medicine.
Sanofi’s third Translate collaboration sees big bucks at last
The deal-hungry French big pharma gives Translate’s mRNA vaccine technology a massive boost.
